Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Jan 1.

Published in final edited form as: Br J Med Med Res. 2014 Jan 1;4(1):139–148. doi: 10.9734/BJMMR/2014/4897

Change in 0–10 Numeric Rating Scale (NRS) Pain Intensity (1A) and validated lower and upper extremity function measures (WOMAC total score and Timed-Stands test for knee patients and SPADI total score for shoulder patients (1B) after first injection and Change in 0–10 NRS after subsequent injections (1C)

1A. Daytime and night-time Pain NRS (0–10) pre- and post-first IA-BoNT/A injection

1B. WOMAC total score (0–100), SPADI total score (0–100) and Timed Stands test (TST, in seconds) pre-post-first IA-BoNT/A injection

1C. Daytime NRS pain after second (n=6) and third (n=5) IA-BoNT/A injections

X-axis represents time since the injection including the pre-injection time-point; in instances, when there are no observations at a specific time-point, the bar is missing. Y-axis represents pain severity from 0–10 numeric rating scale in figures 1A and 1C and the range for functional scale scores (WOMAC for knee and SPADI for shoulder) from 0–100 or timed stands test (TST) in seconds, for figure 1B. For example, in figure 1A, the first bar represents that daytime pain severity before the first IA BoNT-A injection and the next 5 bars daytime pain intensity upto 10–18 months after the first IA BoNT-A injection, showing significant reduction in pain severity from a mean of 7 pre-injection to <2 at the last follow-up (p<0.001 by ANOVA). Each patient received the first IA BoNT-A injection of 100 units.

Similarly, figure 1C provides daytime pain NRS scores before (blue bars) and up to 10–18 months after second and third IA BoNT-A injections, respectively, showing that pain reduction was significant statistically for the second IA BoNT-A injection (p=0.044). IA BoNT-A doses were 100 units each in two joints and 200 units each in four joints. The pain reductions with third injections were not as impressive (p>0.05) and included two refractory patients, who had failed to respond to the first two injections. IA BoNT-A doses were 300 units in two joints and 100 units in three joints. Pain and functional scores were almost normally distributed with no skewed patterns.

Change in 0–10 Numeric Rating Scale (NRS) Pain Intensity (1A) and validated lower and upper extremity function measures (WOMAC total score and Timed-Stands test for knee patients and SPADI total score for shoulder patients (1B) after first injection and Change in 0–10 NRS after subsequent injections (1C)

1A. Daytime and night-time Pain NRS (0–10) pre- and post-first IA-BoNT/A injection

1B. WOMAC total score (0–100), SPADI total score (0–100) and Timed Stands test (TST, in seconds) pre-post-first IA-BoNT/A injection

1C. Daytime NRS pain after second (n=6) and third (n=5) IA-BoNT/A injections

X-axis represents time since the injection including the pre-injection time-point; in instances, when there are no observations at a specific time-point, the bar is missing. Y-axis represents pain severity from 0–10 numeric rating scale in figures 1A and 1C and the range for functional scale scores (WOMAC for knee and SPADI for shoulder) from 0–100 or timed stands test (TST) in seconds, for figure 1B. For example, in figure 1A, the first bar represents that daytime pain severity before the first IA BoNT-A injection and the next 5 bars daytime pain intensity upto 10–18 months after the first IA BoNT-A injection, showing significant reduction in pain severity from a mean of 7 pre-injection to <2 at the last follow-up (p<0.001 by ANOVA). Each patient received the first IA BoNT-A injection of 100 units.

Similarly, figure 1C provides daytime pain NRS scores before (blue bars) and up to 10–18 months after second and third IA BoNT-A injections, respectively, showing that pain reduction was significant statistically for the second IA BoNT-A injection (p=0.044). IA BoNT-A doses were 100 units each in two joints and 200 units each in four joints. The pain reductions with third injections were not as impressive (p>0.05) and included two refractory patients, who had failed to respond to the first two injections. IA BoNT-A doses were 300 units in two joints and 100 units in three joints. Pain and functional scores were almost normally distributed with no skewed patterns.